AmBisome®

DRUG3 trials

Sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., F2G Biotech GmbH, Drugs for Neglected Diseases

Conditions

BioequivalenceInvasive AspergillosisPrimary Visceral Leishmaniasis

Phase 1

A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

CompletedNCT04993222

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Bioequivalence

Start: 2020-06-04End: 2020-11-16Updated: 2021-08-06

Phase 2

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

Active, not recruitingNCT05593666

Drugs for Neglected DiseasesPrimary Visceral Leishmaniasis

Start: 2022-12-27End: 2025-12-30Updated: 2025-12-18

Phase 3

Olorofim Aspergillus Infection Study

Active, not recruitingNCT05101187

F2G Biotech GmbHInvasive Aspergillosis

Start: 2022-03-31End: 2026-11-01Target: 225Updated: 2026-01-06